C-7H02Samsara Therapeutics
autophagy activation, phenotypic screening, iPSCs
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-7H02
C-7H02C-7H02autophagy activation, phenotypic screening, iPSCs
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Our Work — Transatlantic What We Do Our Work Journal Careers Get In Touch Selected Work Stories we’ve told the world. Download Credentials PDF All AI BioTech Cleantech Climatetech Consumer Cybersecurity Deep Tech eCommerce EdTech Entertainment Fintech Healthtech HR Tech Legaltech Marketing Private Equity PropTech Retail Supply Chain Travel VC Samsara Therapeutics 's website Positioning Samsara at the forefront of rare and complex disease research Transatlantic is proud to support Samsara Therapeutics' development of promising new therapies for genetic diseases and neurodegenerative d
Healthspan Capital Home Home About About BLOG BLOG Contact Contact California, USA Rejuvenation is the future of medicine. Investing in early-stage longevity biotech ("LongBio") and regenerative medicine startups to extend healthy human lifespan . Invest IN OUR FUND Aging a new therapeutic target to treat disease. A new wave of biotechnology startups are changing the paradigm on aging, disease, and human lifespan . Where science meets mission. Deep Expertise A decade of combined experience in longevity biotech investment and company creation. Network Unparalleled network of collabora … e of approaches and modalities. Simple and Accessible Healthspan Capital's rolling fund lets investors start investing in longevity in a way that's simple and flexible -- all through AngelList. Portfolio View all Founders Nathan Cheng General Partner Nathan Cheng is the Program Director of the On Deck Longevity Biotech and the Longevity Biotech Fellowship. He is also the founder of Longevity Marketcap, the most widely read newsletter on investing in longevity, Longe … in the biology of aging at the Gulbenkian Institute, awarded the Skaggs-Oxford fellowship at the Scripps Research Institute, and a SENS Foundation Scholar at the Buck Institute for Research on Aging. He was in the DPhil (PhD) program at Oxford as a Clarendon Scholar focusing on the biochemistry of aging, and completed a dual MSc in Life Science Business Management and Molecular Neuroscience from the University of Amsterdam as an Amsterdam Excellence Scholar. Michael Chinen G … s been recognized with several awards, including a Breakthroughs in Gerontology Award from the Glenn Foundation, an Alzheimer’s Association Young Investigator Award, an Ellison Medical Foundation New Scholar in Aging Award, an Undergraduate Research Mentor of the Year Award, and a Murdock Trust Award. In 2011, he was named the Vincent Cristofalo Rising Star in Aging Research by the American Federation for Aging Research and appointed as a Fellow of the Gerontological Society … t Apollo Health Ventures, the first and largest LongBio-focused venture capital fund and company builder in the world. He conducted his doctoral training at the Stem Cell Institute of Harvard University (focused on muscle stem cells) and the University of Copenhagen. He also holds an MSc and BSc in Molecular Biomedicine, a 6 year program at the U
Global Community | Lincoln College Oxford Lincoln College 600th Anniversary home page Menu GLOBAL Lincoln Overview Global Community Undergraduate Scholarships Graduate Scholarships Cutting Edge Research and Teaching Travel Grants FOREVER Lincoln Overview Transformational Bequests Legacies at Lincoln Endowment Fund Support sustainability at Lincoln HISTORIC Lincoln Overview Opportunities for Support 20-27 Lincoln Timeline Merchandise COLLEGIATE Lincoln Overview Community Hubs Welfare Sports and Societies OPEN Lincoln Overview Endow a Bursary Outreach and Access Initiatives Support the 600 Campa … riculation, 1989 Tom Begich Tom Begich is Executive Director of the Nick Begich Scholarship Intern Fund (http://nickbegichfund.org/), and owner/operator of CW Communications, a strategic planning, facilitation, and communications firm specializing in justice, education, and government relations. He has served as Government Affairs Director for the Coalition for Education Equity and serves as a faculty member with Reclaiming Futures, a national juvenile justice/behavior health … and as CJJ National Chair in 1997. Begich is a 2023 recipient of the John Dewey Award for Distinguished Public Service from Bard College. He is also a poet and professional musician with seven CDs and one book of poetry. South America Argentina David Smith, Buenos Aires (1971) Argentina, Buenos Aires Matriculation, 1971 David Smith An award-winning foreign correspondent for Reuters, ITN, Channel Four News and The Economist, he witnessed first-hand many of the major events of … at the New Zealand Embassy in Buenos Aires, managing its development assistance fund and leading analysis of political and economic matters. Having lived in Oxford for two years, Matías holds fond memories of all things Lincoln – from rowing on the Isis and navigating essay crises in the dazzling college library to stimulating talks over formals in Hall. It is nonetheless the many friends made in Oxford that remain the most enduring legacy of his time as a student in the “cit … During his academic pursuits, Hamlet was honored with the prestigious Clarendon Scholarship for his DPhil degree and the Hirschmann Scholarship for his MD degree. Hamlet's commitment to advancing the fields of computational chemistry and drug discovery is evident in his publications and contributions to the scientific community. Oceania Australia
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Tim Piser PhD - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Profile Tim Piser PhD President and Head of R&D at Samsara Therapeutics Tim Piser PhD 's Executive Work History Current President and Head of R&D , President and Head of R&D Equilar on 12/07/2025 Samsara Therapeutics Past To view Tim Piser PhD's complete executive work history, sign up now Education B.S., University of
Apollo Health Ventures - Longevity List Sign in or Register Add a listing View all results No results Jobs Database More arrow_drop_down Clinical Trials Newsletter Coworking Events Blog Supporters About Add a listing opening tag is omitted --> tag --> Apollo Health Ventures ENHANCING HEALTHY LIFESPAN Website Profile prev next Website Bookmark Share prev next General Headquarters Berlin, Germany Founders & Team Alexandra Bause, James Peyer, James Peyer, Nils Regge, Ole Mensching Year Founded 2016 Portfolio Cleara Biotech Samsara Therapeutics About Apollo Health Ventures is an Early Stage Invest … ts right in your inbox. You May Also Be Interested In Healthspan Capital a seed fund supporting longevity and geroscience companies developing therapies that extend healthy lifespan. Seed +2 Methuselah Fund Venture arm of the Methuselah Foundation -- one of the oldest longevity organizations Pre-seed Maximon longevity company builder based in Switzerland Pre-seed Longevity List. 2023. person Sign in Sign in Remember me person Don't have an account? lock Forgot password? perso
Apollo Health Ventures | What we invest in Join us on LinkedIn for the latest news. Contact LP Login What we believe in what we invest in who we are latest from us Contact lp login We use cookies to improve the user experience. You can read more about our Cookie Policy here . Accept our approach We believe that we can generate significant value by actively cofounding ventures which is a core pillar next to investing in best-in-class companies from our outside dealflow We do this by partnering with and enabling leading scientists, research institutes, as well as universities to build transforma
--> Nils Regge | Aeovian top of page Home Science & Pipeline Team Patients News Contact NILS REGGE Director Nils co-founded Apollo Health Ventures in 2017 with the mission to target the root cause of aging and age-related diseases. He has shaped Apollo's strategy as a leading transatlantic venture creation firm and early stage investor in the aging sector. During his tenure at Apollo, Nils has led the firm to various company creations, deals and the successful closing of two fund generations. Next to Aeovian, Nils currently serves on the board of Samsara Therapeutics and other company
Dr Peter Hamley – UKI2S Home About About us Team When & How we invest Investment Areas Defence & Security Engineering Biology Fusion Knowledge Assets Partner Innovation Space Portfolio Our Impact News Pitch for Investment Pitch for Investment Experienced Investment Team UKI2S > About > Team > Dr Peter Hamley “I'm thrilled to be a part of the UKI2S board, contributing to the vital work of the UK Innovation and Science Fund. This fund plays a pivotal role in fostering growth within the UK’s life sciences, biotech, and pharma sectors for the benefit of our economy and natio … ions within the biotech and life sciences sectors. UK Innovation & Science Seed Fund Team View all Team Profiles © UKI2S and Future Planet Capital (Ventures) Limited. All Rights Reserved. UKI2S is managed by Future Planet Capital (Ventures) Limited which is Authorised and Regulated in the UK by the Financial Conduct Authority FRN 148549. Registered in England and Wales. Company Number 2500898. Registered Address: Future Planet Capital (Ventures) Limited, 1 Scott Place, 2 Hard
Kite Ventures — VC Fund Profile | Waveup Copilot Assisted fundraising Log in | Sign up Home Guides Assets Investors VC funds Tailored lists Favorites Academy Privacy policy Terms of Use Privacy Policy Help center Return to waveup.com Fund profile Kite Ventures London, United Kingdom Leading About Kite Ventures is a London-based venture capital firm founded in 2008 by Edward Shenderovich, specializing in marketplace and transactional network investments across Europe and the United States. The firm has invested more than $300 million in over 20 companies across its history and has produced 2 IP … Shenderovich also operates an AngelList syndicate alongside the firm's primary fund activity. Kite Ventures' most prominent exits include Delivery Hero (IPO on the Frankfurt Stock Exchange at a $5.01 billion market cap in June 2017), Darberry (acquired by Groupon), Plated (acquired by Albertsons), and MADE.COM. Other portfolio companies include Ratehawk (accommodation booking for travel professionals), Zenhotels, Ostrovok, Helpling, Fyber, and Samsara Therapeutics. The origi … Ostrovok, Helpling, Fyber, and Samsara Therapeutics. The original Kite Ventures Fund was launched in December 2008, and investments have spanned seed through secondary market transactions in consumer internet, e-commerce, retail, travel, SaaS, and food and beverage technology. Kite Ventures appears to have been in a harvest-oriented phase since approximately 2020, with the last recorded new investment being Samsara Therapeutics in drug discovery in December 2019. Shenderovich … ite kiteventures.com Email [email protected] Social Lists that include this fund
In 2024 our portfolio companies have shown remarkable resilience while navigating the global macro environment, and we are optimistic about 2025. Increased M&A activity has created a compelling… | infinitas capital LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices … Capital , based in West Palm Beach, has successfully closed its inaugural $325M fund focused on development-stage biotechnology companies. The firm was founded in 2023 by Dr. Evan Rachlin and Dr. Lorence Kim , both former Moderna executives who bring deep operating and investment expertise. What makes this particularly noteworthy: Ascenta's team has contributed to 30+ approved medicines throughout their careers, and they've already deployed over $100M across six portfolio com … at are collectively running 14 clinical trials with 40+ pipeline programs. This fund close reinforces South Florida's emergence as a legitimate medtech hub. The region attracted $572.5M in medtech funding across 45 deals in 2024, with companies like Insightec, DermaSensor, and others leading the charge. The combination of institutional capital, experienced operators, and a growing talent base is creating real momentum in our biotech sector. Learn more about their portfolio an … al Emergence 2026 Conference in Sydney in February. For High-Profile Investors, Fund Managers & Family Offices: 🤝 Gain exclusive, curated access to a pipeline of high-potential, investor-ready companies in a critical growth sector—Australia's life sciences industry. 🤝 Bridge the gap between world-class innovation and the private capital seeking deep-tech and future-focused opportunities. We are now accepting expressions of interest from companies that would like to part … rs - Bpifrance , Andera Partners , Angelini Ventures , Surveyor Capital , aMoon Fund , and existing shareholders Pontifax Venture Capital , Dawn Biopharma, Pureos Bioventures , and RA Capital - on this milestone! More information on : https://lnkd.in/e4ieWmJJ #Biotech #VentureCapital #LifeSciences #KurmaPartners #ADCs #Innovation 170 1 Comment Li
Research We Fund | CMT Research Foundation Research We Fund | CMT Research Foundation What is CMT? About CMT Type1 What is CMT1A? What is CMT1B? What is CMT1E? What is HNPP? Type2 What is CMT2A? Type4 What is SORD? TypeX Understanding CMT1X/CMTX1 and GJB1 —- Watch Our Video Series Learn About Treatments in Development Research Research Approach Research Projects We Fund Research Pipeline Gene Therapy Clinical Trials —- Apply for Funding Emerging Researcher Award News & Stories News CMT Stories Take Action About Us Who We Are Board of Directors Research Advisory Council Scienti … MT Research Convention Donate Research Funded by the CMT Research Foundation We fund innovative research that has the potential to be quickly translated into treatments. Active Projects Research Partner Key Focus Advancing Gene Therapy Promoting Nerve Health Overcoming the Delivery Challenge De-Risking Clinical Trials Status Johns Hopkins University, Jeremy Sullivan and Charlotte Sumner Find a blood-based biomarker that could measure whether future CMT treatments are working
The ALS Association | Portfolio, Investments & AUM | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Investors The ALS Association The ALS Association Arlington, Virginia als.org Overview The ALS Association is a non-profit organization that funds global research into amyotrophic lateral sclerosis (ALS) through grants and awards to advance the search for new treatments and a cure. Year Founded 1985 Portfolio Companies 13 Website als.org Investments Company Date Stage Lead Molefy Pharma Oct 2025 Grant Co-invest … ny Date Stage Lead Molefy Pharma Oct 2025 Grant Co-investor Modulo Bio Feb 2025 Grant Co-investor Samsara Therapeutics Oct 2024 Grant Co-investor Myrobalan Therapeutics Feb 2024 Grant Co-investor InFlectis BioScience Jan 2024 Grant Co-investor View all investments Key People Amber Stalker Managing Director, Care Services At The ALS Association, Northeast Territory Caroline Roberson Managing Director-Advocacy Christine Duque Managing Director Of Development Diana Arevalo Manag
Samsara - Today, we're announcing $50 million in new... Facebook Log In Samsara's Post Samsara March 22, 2018 · Shared with Public Today, we're announcing $50 million in new growth capital from Andreessen Horowitz and General Catalyst to accelerate product innovation and rapidly scale customer support. Thanks to our great team, customers, and investors! samsara.com Enterprise IoT Leader Samsara Raises $50M to Invest in Growth - Samsara All reactions: 94 4 comments 11 shares Like Comment Most relevant Sam Houston Good maybe we can get all of the features to work, like the one whe
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
New Zealand and Ireland-based... - Enterprise Ireland Facebook Log In Enterprise Ireland's Post Enterprise Ireland December 20, 2024 · Shared with Public New Zealand and Ireland-based start-up Marama Labs has opened a new life sciences applications lab at Dublin City University’s (DCU) innovation campus, DCU Alpha. The company also announced that it has secured €2m in funding to support the expansion of its upcoming product, CloudSpec. The company plans to use the funding to support its flagship product in the mRNA therapeutics market. Read more https://shorturl.at/nP7dg All reactions: 3
Samsara, founded by John Bicket... - MIT Alumni Association Facebook Log In MIT Alumni Association's Post MIT Alumni Association March 17 · Shared with Public Samsara, founded by John Bicket SM ’05 and Sanjit Biswas SM ’05, helps construction, logistics, energy, and manufacturing companies with large physical operations get work done more intelligently. Its platform tracks and learns from workers, equipment, and other infrastructure to prevent accidents, reduce risks, and save fuel. https://bit.ly/4cBqfJ8 All reactions: 18 Like Comment
%PDF-1.5 %���� 1508 0 obj > endobj 1559 0 obj >/Encrypt 1510 0 R/Filter /FlateDecode/ID [(\230\226G\234\035\330rU,DmJ \016\005!) (\230\226G\234\035\330rU,DmJ \016\005!)]/Index [1508 52]/Info 1506 0 R/Length 105/Prev 9287790/Root 1509 0 R/Size 1560/Type /XRef/W [1 3 1]>> stream x�cbd```b``z "�zA$k>X�L����`�,� "��"�`,� f��Cj��I@RTp���"��"��c%�� �������w�{�k�=$�3� endstream endobj startxref 0 %%EOF 1509 0 obj >/AcroForm 1530 0 R/Metadata 731 0 R/OCProperties > > > > > > > > > > > > > > > > > > > > >]/OFF []/ON []/Order []/RBGroups []>>/OCGs [1544 0 R 833 0 R 914 0 R 934 0 R 1048 0 … �Q �J��,��ѣ�E�'Z{�C����? 0�!Ȃ�����\�.Ȱ ��.�C�`���F,;��w��n��p��&S����8�RFP��O�6��C���� �=��J�33�@�8�M-�V ��Z=����(Bez��E_녌q�\��C�y�4B�s�� s W!�-�\^��7� �����dE��̉btδ=�;��Oh�Y f�He1|s�ɠ���h��n�~����j�#�B���`�[B��L�k2�����!�5/��+�PW盕�u傃X�n�Ȅ�H�*�&�4��WS���� ������т$��D8@|�s�u��2���k��v�VO�I �Y΅ќ!ɻc8%��$��l�S�ڤ�|2�V�K�� Y��K��z{�`9� L��X�0���M # 3�SUN����#k0g��v���� ���i�}���5^?� R����h`����]��J���pg� �s�_|��y4�;.�%�������V .� … �� B��C��L(�B�y�lM�xG�bx"�%�V�����8�Ɵ�G �����%������=��`��vN� }��%?� |% 4 RfP{~�ץ �^�'ȥ���"�j��I�אއ:A�T^م1 ��m����+7�� ��� +@���- CI9r ����y; ��:1m�,��-���go/eC�M�Z2u�Mlm~HS]*r���F�n�I̝��%d�oɏ9�j����f�w��C�ڲx"�ҟF���K!���% ���/Ѩ �QK�.io3>2��vI�E����K���S�$D�^\����{ ::��\I�H��("_}��PY�%����^ԋ'�_u��u���I���&��S�"F䠢�S]fYH2�~k���q�#�瞂��4�gЉH�j :�lH���7#���-Q���C�_� 㲉�N�L���P3 ��!&�h�MC��fϑ��)� O9��)"��ܗ�����m�db�@L���|&X��w�7V�
Scripta Therapeutics raises $12m to flip the script on drug discovery - European Biotechnology Magazine ADVERTISEMENT Stay up to date every week with the european biotechnology newsletter. ✕ Comments This field is for validation purposes and should be left unchanged. Email (Required) This field is hidden when viewing the form EBcom NL confirm list This field is hidden when viewing the form Consent I agree to the privacy policy. Stay up to date every week with the european biotechnology newsletter. Log in here to read the desired article. Facebook This field is for validation purposes an
Report: Cambrian Business Breakdown & Founding Story | Contrary Research Companies Reports Foundations & Frontiers Tech Trends Report Conversations About Powered by Discover Companies Reports Foundations & Frontiers Tech Trends Report Conversations Fellowship About Connect Email LinkedIn Twitter Subscribe Powered by © 2026 Contrary Research · All rights reserved Privacy Policy By navigating this website you agree to our privacy policy . Deny Accept Overview Memo Authors 1 Resources 7 Similar Companies 9 Share Cambrian Biotech Cambrian Bio is a biotech company with multiple programs … his collaboration ultimately led to an invitation to establish a new investment fund based in Germany. In 2016, Peyer co-founded Apollo Health Ventures , a fund dedicated to creating and investing in biotech companies developing therapies that target the mechanisms of aging. It was through Apollo that Peyer met Brunemeier. Brunemeier had begun a joint Ph.D. program at Scripps and Oxford studying the biochemistry of aging before leaving academia to launch new companies full-ti … stant depression. With a personal interest in slowing aging, Angermayer and his fund, Apeiron Investment Group , would go on to provide the financial foundation for Cambrian’s launch, anchoring the company’s $60 million raise as it emerged from stealth in 2021. As Cambrian expanded, James invited Juliette Han to join Cambrian as COO and CFO in 2020 . Han was a former mentor to James at McKinsey and before Cambrian, she was Chief of Staff at Two Sigma Investments, COO of peopl … 00 million in October 2021. The financing was co-led by Anthos Capital and SALT Fund, with existing investors such as Apeiron Investment Group (co-founder, Angermeyer’s fund), Future Ventures, and Moore Capital also investing in the round. Several of Cambrian’s portfolio companies have raised capital as well. As of November 2025, Amplifier Therapeutics has raised a total of $33.3 million , all of which came from its Series A round led by Future Ventures and RA Capital Managem … onomists at MIT proposed that biotech productivity could improve when companies apply principles of portfolio theory. They suggested that isolating scientific bets into independent entities reduces correlated risk and creates the opportunity to raise program-level debt. This is a feature that has enabled Bridge Bio to achieve three FDA approvals
Samsara Therapeutics unveils promising autophagy drug candidate, offering new hope for people with Parkinson's and Motor Neurone Disease - Samsara Therapeutics | Samsara Therapeutics | 10 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in yo
--> Accelerating Drug Discovery with Next-gen Proteomics | An Evening with Biognosys - Biognosys --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> in Everywhere Solutions News & Events Resources --> --> Proteomics About Proteomes and Proteomics Large-Scale Proteomics Our Technology Our Facilities Solutions Services CRO Services HIDDEN CRO Services Data Insights View all Data Insights HIDDEN Proteoverse® Software View all software Software Spectronaut® SpectroMine™ SpectroDive™ QuiC™ OmicsFlow® Kits View all kits Kits Pep
Each year, Nature Biotechnology... - Nature Portfolio Facebook Log In Nature Portfolio's Post Nature Portfolio Verified account July 13, 2024 · Shared with Public Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Empress Therapeutics is reverse-engineering microbial manufacturing. Read the article: https://go.nature.com/3Y0LQDE All reactions: 22 6 shares Like Comment
Error - UK Trade Info Skip to main content UK Trade Info Sorry, there is a problem with the service Try again later. Contact us if you need help. Trade data or general enquiries Customer services Email: [email protected] Phone: 03000 594 250 Opening times: Monday to Friday: 9am to 4pm Closed on bank holidays. Intrastat enquiries Intrastat Email: [email protected] Phone: 03000 594 231 Opening times: Monday to Friday: 9am to 4pm Closed on bank holidays. All content is available under the Open Government Licence v3.0 , except where otherwise stated © Crown copyright
Samsara Therapeutics Careers, Perks + Culture | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies Samsara Therapeutics Teams Samsara Therapeutics Save Saved Oxford 21 Total Employees Year Founded: 2018 View Website Overview Jobs Offices Is This Your Company? Claim Profile Healthtech Biotech Pharmaceutical Samsara Therapeutics, Inc. is biopharmaceutical company aiming to discover first-in-class therapeutics that treat rare genetic and neurodegenerative disease, and extend healthy lifespan. Samsara's pl
%PDF-1.7 %���� 1 0 obj > endobj 2 0 obj /Company /CreationDate /Creator /ModDate /Producer /SourceModified >> endobj 3 0 obj > stream ~����� /4vm@��4g�O �1*�/��s��9u}g 8�H�[f�@R� o��f�qm�a�[��;�H^7�M{ur4�����:[9�b���.���Ʌ���I Qے21��G�5[U dž3�~�/��� P��2@�}� %�.�灌C^�"es��6�EO� > endobj 5 0 obj > endobj 6 0 obj >> endobj 7 0 obj >> endobj 8 0 obj > /Font > /ProcSet [ /PDF /Text /ImageB /ImageC /ImageI ] /XObject > >> /Rotate 0 /StructParents 0 /Tabs /S /Type /Page >> endobj 9 0 obj > /Font > /ProcSet [ /PDF /Text /ImageC ] /XObject > >> /Rotate 0 /StructParents 1 /Tabs /S /T
CMTRF funding for Samsara Therapeutics CMT treatment Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse by sector
Samsara Therapeutics Inc. - Page 1 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib mark
Research | VitaDAO WHY LONGEVITY RESEARCH VITA LABS VITA TOKEN PROJECTS BLOG STORE GET VITA LOADING VITADAO RESEARCH A global community on a mission to solve aging VitaDAO unites talent, resources, and capital through a decentralized and transparent model that empowers individuals to drive innovation in aging research. We enable efficient capital allocation to early-stage biotech research projects and ensure that resulting intellectual property remains community-owned and equitably distributed. JUMP TO: RESOURCES EXPLORE PROJECTS WE OFFER a new model for funding, advancing and commercializing … l therapeutics in an equitable, Permissionless and democratic way. LEARN HOW WE FUND RESEARCH USING IPTs FUNDING IRL SCIENCE ONCHAIN 31 Projects Funded $4.7M Funding Deployed $60.0M Projects FDV 3 Target Discovery Projects 18 Drug Discovery Projects 3 Preclinical Drug Dev Projects 3 Clinical Drug Dev Projects 8 IPTs Generated 3 Companies Founded FUNDING IRL SCIENCE – ONCHAIN 31 Projects Funded $4.7M Funding Deployed $60.0M Projects FDV 3 Target Discovery Projects 18 Drug Disc … lthspan Capital, and Principal at Apollo Health Ventures, the largest longevity fund in the world, CIO and Co-Founder at Cambrian Biopharma, and Founder of Samsara Therapeutics. He was a DPhil (PhD) Clarendon Scholar in Biochemistry at the University of Oxford before taking leave of Oxford to co-found Cambrian, a Fulbright Fellow, a Skaggs-Oxford Scholar at the Scripps Research Institute, and holds a dual MSc in Molecular Neuroscience and Biotech Business Management from Univ … agement from University of Amsterdam. He is an advisor to the Longevity Biotech Fellowship. Read More AUBRAI On-chain AI Agent AUBRAI is an on-chain AI agent accelerating longevity research. Built with Dr. Aubrey de Grey's expertise, it synthesizes papers, critiques study designs, and shares live updates about RMR2. At the heart of AUBRAI's mission lies the Robust Mouse Rejuvenation (RMR2) project - an ambitious study to double the remaining lifespan of middle-aged … abs, our incubator program for early stage longevity research. LEARN MORE & APPLY HOW VITADAO FUNDS RESEARCH WITH IPTS An IPT (short for Intellectual Property Token) is a digital token that represents ownership, licensing rights, or financial interest in a specific piece of intellectual property—typically a patent, research asset, or therapeu
BBC Oxford: Samsara Therapeutics | Peter Hamley LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and
Samsara Therapeutics | Storyboard Job Board The StoryHouse Jobs Board Welcome to the StoryHouse Jobs Board, a place to explore career adventures at start-ups and companies founded by Claremont alumni and the Claremont community. Choose your next adventure at a company where you’ll have an edge from day one, and leverage our Claremont network to build your career. Also, make sure to check out our newsletter, StoryHouse Review , to find out more about these companies in the Claremont ecosystem. Search jobs Explore companies Join talent network Talent My job alerts Samsara Therapeutics samsarathe
OxBio Summit – Oxford University Biotech Society Skip to content Home About Us Menu Toggle Our Story Our Team Events Menu Toggle Consulting Menu Toggle White Papers IGNITE OxBio Summit Termcard Sponsors & Partners Insights Menu Toggle White Papers Biotechnology Trend Review Contact Us Sign up Sign up Main Menu Home About Us Menu Toggle Our Story Our Team Events Menu Toggle Consulting IGNITE OxBio Summit Termcard Sponsors & Partners Productions Menu Toggle Journal Podcast Contact Us Speakers TRANSLATING DISCOVERIES TO IMPACT A flagship annual biotechnology summit connecting academ … University of Oxford, South Parks Road, Oxford, OX1 3EL Register for the Summit Apply for the Startup Showcase About Why Attend Programme Agenda Speakers Partners About Why Attend Programme Agenda Speakers Partners ABOUT THE SUMMIT Advancing biotech from discovery to impact OxBio Summit is a flagship, annual biotechnology summit hosted by the Oxford University Biotech Society. Through cross-sector dialogue, interdisciplinary collaboration, and knowledge exchange, the summit a … ights to First-in-Human Studies Biotech Career Trajectory & Talent Pathways APPLICATION NOW CLOSED Startup Showcase Early-stage biotech startups and spinouts are invited to join the summit, showcase their company and connect with researchers, investors, talent, and ecosystem partners. Submit Showcase Application AGENDA Saturday, 09 MAY 2026 08:30 - 09:00 Registration & Networking 09:00 - 09:15 Welcome Address Eren Akgun 09:15 - 10:00 Opening Keynote: Building the UK's … obal (EIT) David Rossow Founding Partner, Gates Foundation Strategic Investment Fund Nihal Sinha Partner, F-Prime Capital Click for Bio Sutha Satkunarajah VP Strategy & Operations, Flagship Pioneering UK Click for Bio Laura Lane VP Lilly Ventures (Head of Europe), Eli Lilly & Company Click for Bio Craig Fox Operating Partner – Life Sciences, Oxford Science Enterprises Click for Bio Simon Warner Head of Licensing & Ventures – Life Sciences, Oxford Unive … t attendance and showcase applications are handled separately. Startup showcase application now closed Our Team David C. Michael Chair & Organiser Second year DPhil in Clinical Medicine VP Institutional Relations at OUBT Experience in management consulting and biomedical sciences research Yushi Li Co-Organiser First year DPhil in Molecular Cell B
%PDF-1.5 %���� 991 0 obj > endobj 1030 0 obj >/Encrypt 993 0 R/Filter /FlateDecode/ID [(\351\201\316\323n\)\004\354\215 \361\204@\013\305 > stream x�cbd```b``�"9@$���,�&�@$C�d^��v˚�Ii0��`3G��6`� XW4�����o�X��� �4!�302~db�k�����!� � endstream endobj startxref 0 %%EOF 992 0 obj >/AcroForm 1013 0 R/Metadata 397 0 R/OCProperties >/OCGs []>>/OpenAction 1012 0 R/PageLayout /SinglePage/PageMode /UseNone/Pages 629 0 R/StructTreeRoot 651 0 R/Type /Catalog>> endobj 993 0 obj > endobj 1028 0 obj > stream N\�� �]�A�8>�nA�#�� 5vَ�҉�yg� Pu�ذ���C�J7A����,�=�5���'����ꌇS�دr#L�ܛ[�)bw�� hM��U�
Samsara Therapeutics is Developing Anti-Aging Drugs Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse by sector
Dermatology Summit 2024 - Advancing Innovation in Dermatology Twitter LinkedIn Menu About About Vision / Mission Our Strategic Partners Success Stories People Executive Committee & Board of Trustees Conference and Program Leadership Platform Programs AID Accelerator Leadership Councils Previous Programs Conferences Dermatology Innovation Forum 2026 Dermatology Summit 2026 Collaborations Itch Insight Media Events Contact Search START TYPING AND PRESS ENTER TO SEARCH About About Vision / Mission Our Strategic Partners Success Stories People Executive Committee & Board of Trustees Confe … CLA. He is a board-certified dermatologist and emergency medicine physician and fellowship trained in dermatologic surgery and cutaneous oncology. Frederick completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children's Skin Disease Foundation and Camp Wonder. He is o … stry from Wayne State University in Detroit, Michigan, and did his postdoctoral fellowship at the Institut de Chimie des Substances Naturelles (ICSN) and the Ecole Polytechnique in Paris, France. Timothy Piser, PhD Head of R&D Samsara Therapeutics + Click here to View Biography Biography Dr. Timothy Piser is a neuropharmacologist with more than 25 years of experience leading neuroscience drug discovery and development in large public pharmaceutical companies and private VC-fu … the Ludwig Maximilians University in Munich, Germany, and did his postdoctoral fellowship with David Evans at Harvard University working on total synthesis of antibiotics. Vittorio Sebastiano, PhD Co-Founder & Head of Research Turn Bio Associate Professor of OBGyN Stanford School of Medicine + Click here to View Biography Biography Dr. Vittorio Sebastiano is an Associate Professor of OBGyN at Stanford School of Medicine. His lab has established a new technology named ERA (Ep … -founder and Head of Research. In 2009, Dr. Sebastiano completed a postdoctoral fellowship at the laboratory of Dr. Marius Wernig at Stanford University, where he implemented the newly discovered iPSC technology and was among the first to demonstrate that iPSCs can be efficiently derived, genetically modified, and implemented for cell therapy in
Novasenta - aVenture Company Research Home Research Loading aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions. aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcas
Apollo Ventures Funds Autophagy Enhancement Startup Samsara Therapeutics – Fight Aging! Home FAQ Fund Research Services Investing Therapies Newsletter Archives Press Room Resources About Fight Aging! Do you want to live a longer life in good health? Simple practices can make some difference, such as exercise or calorie restriction. But over the long haul all that really matters is progress in medicine: building new classes of therapy to repair and reverse the known root causes of aging. The sooner these treatments arrive, the more lives will be saved. Find out how to help » March 5 … Living Longer Read the Fight Aging! FAQ Sign up for the Fight Aging! Newsletter Fund Meaningful Aging Research Services Longevity Industry Consulting How to Start a Longevity Biotech Company The Root Causes of Aging Aging is Caused by Damage Accumulating Cross-Links Buildup of Amyloid Between Cells The Failing Adaptive Immune System The Failing Innate Immune System Declining Lysosomal Function Mitochondrial DNA Damage Nuclear DNA Damage Buildup of Senescent Cells Archives and … Feed RSS Comments Feed Using the Fight Aging! Content Feeds Required Reading A Proposal to Accelerate Progress Calorie Restriction and Longevity Cryonics, the Necessary Backup Plan How to Argue for Longevity Science The Odds of Human Longevity Mutations The Need For Activism and Advocacy Nuanced Opposition to the FDA Potential Gene Therapy Targets Predicting the First Rejuvenation Therapies Self-Experiment to Fight Aging! SENS: Bringing an End to Aging Stem Cells and Regener … ht Aging!. Home | FAQ | Fund Research | Services | Investing | Therapies | Newsletter | Archives | Press Room | Resources | About Read our terms and conditions and privacy poli
Peter Hamley - BioFIT Speaker Skip to content December 10 th & 11 th , 2026 15 th edition MARSEILLE, FR Linkedin 0 items 0 items 0 items Main Menu Menu Discover BioFIT BioFIT at a glance Organisers Steering Committee BioFIT x MedFIT News Press & Communication kit Programme Conference sessions Pitch sessions Start-up Slams Research & Licensing Partnerships Animal Health Presentations Previous edition Partnering One-to-one meetings Networking evening BioFIT 2025 partnering platform Participants Who will you meet? Supporters / Media Previous edition Exhibition Exhibition fees 2026 E … te is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. WARNING: Some fraudulent companies are supposedly providing the attendees list of BioFIT. And some are passing themselves off as being BioFIT organisation members and asking you to pay. Please note that the BioFIT team will never sell you the BioFIT attendees list and never ask for your bank account details to make you pay for hotel bookings, exhibition fees or others, and certainly not ove … } {title} Manage consent Cart Have a coupon ? If you have a coupon code, please apply it below. Apply coupon Your cart is empty! Return to shop Cart - €0.00 0 1 Scroll to Top
--> Proxy Statement (Form DEF 14A) - Insurance News | InsuranceNewsNet Sign in Subscribe About Advertise Contact Home Now reading Newswires --> Topics Submit --> Advisor News Annuity Index Annuity News Companies Earnings Fiduciary From the Field: Expert Insights Health/Employee Benefits Insurance & Financial Fraud INN Magazine Insiders Only Life Insurance News Newswires Property and Casualty Regulation News Sponsored Articles Washington Wire Videos ——— About Meet our Editorial Staff Advertise Contact Newsletters Life Insurance Annuity News Health/Employee Benefits Propert … sly recommends that you vote FOR the election of the director nominees, and FOR Proposal Nos. 2, 3 and 4. Your vote is important. Whether or not you plan to attend the Annual Meeting, please vote by Internet, by telephone or by completing, signing and dating the accompanying proxy card and returning it as soon as possible. If you have received and are using an enclosed retuenvelope, no postage need be affixed if it is mailed in the United States . If you receive more than one … April 11, 2025 TABLE OF CONTENTS Information About the Proxy Process and Voting Proposal No. 1. Election of Directors Director Compensation Proposal No. 2. Ratification of Selection of Independent Registered Public Accounting Firm Audit Committee Report Proposal No. 3. Advisory Vote on Executive Compensation Proposal No. 4. Approval of the Amendment to the MacroGenics, Inc. 2023 Equity Incentive Plan Corporate Governance Certain Relationships and Related Party Transactions Ex … a unique link that will allow you access to the Annual Meeting and to vote and submit questions during the Annual Meeting. As part of the registration process, you must enter the control number located on your proxy card, voting instruction form, or Notice of Internet Availability (the "Notice"). If, on the Record Date, you are a beneficial owner of shares held in an account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial owner of … instructions on how to access the Proxy Materials over the Internet and how to submit your proxy via the Internet. The Notice also contains instructions on how to request a paper copy of the Proxy Materials. All stockholders who do not receive the Notice will receive a paper copy of the Proxy Materials by mail or an electronic copy of the Proxy
Very excited to see and be part of a new partnership between us, here at Samsara Therapeutics, and CMT Research Foundation. CMT (Charcot-Marie-Tooth) disease are a group of hereditary peripheral… | Matthew Williamson LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices a
PULSE: Empowering the future of UK biotech | BIA Skip to content Influencing policy Business environment Finance and tax IP and tech transfer Regulation Skills and talent Manufacturing Medicines Access to medicines Cell and gene therapy Antimicrobial Resistance Use of animals in research Critical technologies Biosolutions Engineering Biology TechBio Genomics mRNA Growing the sector Skills, talent and people Sector jobs Resources Future talent Diversity and inclusion Invest in biotech Women in Biotech Developing your company Protecting your company BioStart: for early-stage entrepreneurs Search … our company BioStart: for early-stage entrepreneurs Search sector opportunities Submit a sector opportunity Innovation Map Become a member BIA Membership directory Member benefits Your guide to navigating the BIA website Join BIA member community Save with Business Solutions Join BIA Interested in membership? Enquire about joining BIA News and insights Resources Member news Submit member news Press releases Media centre Sign up to Newscast Blogs Blog guidelines Reports BIA in … lines Reports BIA international Events BIA Events BioSolutions UK Sector events Submit sector events London Life Sciences Week Supporting BIA events Event FAQs About What is biotech? Meet the team Our board Articles of Association Charity partnership Our charity partnerships Careers Our supporters Login/Register Join BIA You are here: BioIndustry Association News and insights Resources PULSE: Empowering the future of UK biotech New alumni case studies added for 2025! Foreword … other companies or building research collaborations with other teams to secure grant funding and deliver important proof of concept data. Coming from a scientific background, it’s easy to assume that the technical side of the business will be straightforward. However, it’s important to stay focused on the commercial aspects of the technology in order to build a successful business, and not be distracted by research activities that won’t directly lead … aling £2.6 million. That includes two Biomedical Catalyst grants, a Smart grant, and a Woman in Innovation award. In 2021, we raised £700,000 in pre-seed investment, led by Venrex, and in 2024, we closed an ASA round with participation from Evenlode Investment, Kayan Ventures, and some notable angels. We’ve also been recognised
Samsara Therapeutics Company Overview, Contact Details & Competitors | LeadIQ Learn more at LeadIQ.com Start free Insights Similar companies Tech Stack Media & News Email Format FAQ Insights Innovative Neurodegeneration Focus Samsara Therapeutics specializes in autophagy activation for treating age-related neurodegenerative diseases such as Parkinson's and ALS, presenting opportunities for partners in neurodegenerative drug development and diagnostics. Strategic Industry Partnerships The company's collaboration with research foundations and leading experts like Dame Pamela Shaw … prevent disease and increase health span, has announced that it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to further its research into a promising Parkinson’s disease drug. Jun 11, 2023 | www.htworld.co.uk CMT Research Foundation, INC. partners with Samsara Therapeutics Inc. The partnership with Samsara Therapeutics represents CMTRF’s largest investment to date and is dedicated toward a project to further optimize pipeline autoph
ALS Clinical Trials and Research | “With $30 million in Series A funding, Tranquis Therapeutics launches with a mission of revolutionizing the management of neurodegenerative and agin...
Privacy Policy - Samsara Therapeutics Skip to content Leadership Contact Privacy policy These terms and conditions outline the rules and regulations for the use of Samsara Therapeutics website. Samsara Therapeutics legal address is located at: 16192 Coastal Highway Lewes, Delaware 19958 United States of America By accessing this website we assume you accept these terms and conditions in full. Do not continue to use Samsara Therapeutics website if you do not accept all of the terms and conditions stated on this page. The following terminology applies to these Terms and Conditions, Privacy State … Policy applies only to information we collect through the Website and does not apply to our collection of information from other sources. This Privacy Policy, together with the Terms and conditions posted on our Website, set forth the general rules and policies governing your use of our Website. Depending on your activities when visiting our Website, you may be required to agree to additional terms and conditions. Website Visitors Like most website operators, Samsara Therape
EX-99.(C)(12) 4 d539087dex99c12.htm EX-99.(C)(12) EX-99.(C)(12) Exhibit (c)(12) PROJECT PACIFIC STRATEGIC PROCESS UPDATE MAY 24, 2023 Confidential PROJECT PACIFIC STRATEGIC PROCESS OUTREACH SUMMARY SUBMITTED PROPOSAL (N=8) (1) (1) (1) (1) (1) (1) (1) (1) POTENTIAL INVITE TO PROCESS (N=3) PASSED (N=1) FINANCIAL BUYERS TO CONSIDER CONTACTING (N=3) (1): Indicates executed CDA. Confidential 1 PROJECT PACIFIC HOW COUNTERPARTIES ARE VALUING PACIFIC AND THEMSELVES $ IN USD MILLIONS. SORTED ALPHABETICALLY. PACIFIC VALUATION COUNTERPARTY PF OWNERSHIP ASSETS / PRO FORMA TARGET PIPE PARTY CASH LISTING TE … n solid tumors • BBI-355 in oncogene amplified cancers – June 2023: Submit proposal cancer – 3Q23: Phase 1a monotherapy PD data – Mid-2024: Phase 1/2 clinical POC data – July-August 2023: Funding signal – 2H23: Global Phase 2 TRUST-II interim – 2H23: Initiate Phase 1a/b anti-PD1 • BBI-825 in oncogene amplified cancers – September 2023: Contract data combination trial – 4Q23: IND filing • AER003 / AER004 / AER00 … 5M (includes $2M current cash position and ongoing insider-led round which will fund • ANHEART: $250M (includes $5M of cash expected at 09/30/23 and $5M from ANHEART strategic AERIUM through September 2023) partnership) Implied Valuation (1) • PACIFIC: $45M (based on $40M net cash at close + $5M for Nasdaq listing) • PACIFIC: $150M (based on $140M net cash at close + $10M for Nasdaq listing) Post-$ Last Round / • AERIUM’S post-money from last pri … mmitment to any potential PIPE • AERIUM pursuing ~$280M BARDA contract to fund development to EUA and launch Concurrent Financing • ANHEART has also explored entering $30M investment from SDIC at $250M pre-money (not included • AERIUM ongoing insider-led round to fund company through September 2023 in $40M of commitments from insiders and licensing partner) (2) • Pro forma cash (excl. ~$280M BARDA contract): $40M (AERIUM: $0M expected at 09/30/23 ; (1) … (~$280M) – 2H23: Global Phase 2 TRUST-II interim data – June 2023: Submit proposal – 4Q23: Complete enrollment of global Phase 2 TRUST-II – July-August 2023: Funding signal – 1H24: Initiate global Phase 3 TRUST-III confirmatory study Timing of Key – September 2023: Contract – 2Q24: Pre-NDA type B meeting
CMT Research Foundation and Samsara Therapeutics Partner on a Novel Therapeutic Approach for CMT1A with the Potential to Reach Clinical Trials | CMT Research Foundation CMT Research Foundation and Samsara Therapeutics Partner on a Novel Therapeutic Approach for CMT1A with the Potential to Reach Clinical Trials | CMT Research Foundation What is CMT? About CMT Type1 What is CMT1A? What is CMT1B? What is CMT1E? What is HNPP? Type2 What is CMT2A? Type4 What is SORD? TypeX Understanding CMT1X/CMTX1 and GJB1 —- Watch Our Video Series Learn About Treatments in Development Research Research Appr … About Treatments in Development Research Research Approach Research Projects We Fund Research Pipeline Gene Therapy Clinical Trials —- Apply for Funding Emerging Researcher Award News & Stories News CMT Stories Take Action About Us Who We Are Board of Directors Research Advisory Council Scientific Advisory Board Research Foundation Staff Events Financials Contact Us Velocity Global CMT Research Convention Donate News & Stories See the latest news about CMT drug
Funded Projects - Target ALS Skip to main content Search Donate Our work Our approach Fund Enable Conduct Our impact Funded projects The ALS Global Research Initiative Annual meeting For scientists Funding opportunities Research cores Target ALS Data Engine Longitudinal Biofluids Core Human Postmortem Tissue Core Stem Cell Core Reagents Core Animal Models Core Genomics Core Latest research news Understanding ALS About ALS The current state of research Voices of ALS Get involved Ways to give Fundraise for ALS research Donate now Join our community Participate in research Community-Based Pop-Up … ories Donate Close Search Home Funded Projects Funded Projects Every project we fund aims to move us closer to better diagnostics, earlier detection, and effective treatments. What is our model for research? At Target ALS, we fund the most promising research ideas from around the world with a goal to make sure they don’t stay stuck in silos. Our model connects scientists, data, tools, and funding to move discovery from the lab bench toward real treatments faster than ever bef … bench toward real treatments faster than ever before. Our funding portfolio We fund across the full spectrum of ALS research: 41% of funding goes toward understanding ALS biology Uncovering root causes to identify new therapeutic targets 25% of funding goes toward accelerating drug discovery Translating ideas from the lab into viable treatments 33% of funding goes toward developing biomarkers Enabling earlier diagnosis and reliable tracking of disease progression Target ALS … ealth System), Molly Gale-Hammell (NYU Langone Health System) Target ALS Awards Grant to Advance TDP-43 Cryptic Biomarkers in ALS Target ALS has awarded funding to a project led by two prominent ALS researchers to detect cryptic peptides associated with TDP-43 pathology, seen in ~97% of ALS cases, for biomarker development. This work could produce a reliable, non-invasive way to monitor disease progression and response to treatment in people living with ALS. Generation of ant … FL Switzerland Target ALS Awards Three Projects with Novel Modalities Consortia Grant Three research consortia have been awarded Target ALS funding to develop next-generation gene therapies for ALS. This competitive initiative was designed to accelerate cutting-edge research aimed at developing novel DNA- and RNA-targeting therapies for both spor
Samsara Therapeutics | Lifespan Research Institute Donate Login About Mission Board of Directors Scientific Advisory Board Team Annual Reports Contact Research Supported Projects Investments Publications Education Summer Scholars Post-Baccalaureate Host Lab Signup News Outlet Investor Network About Join Reports Advocacy Video Initiatives Engaging the Press Crowdfunding Sponsored Projects Advocacy Topics A4LI Resources Rejuvenation Roadmap Infographics Longevity Topics Find Longevity Events EARD Conference Archive Get Involved Donate Be a Lifespan Hero Hall of Heroes Join the Lifespan Alliance … iding details as to the disease model or the symptoms reversed. An October 2024 grant announcement disclosed that those results had been generated in a transgenic mouse model of ALS in which the mice produce a disease-causing human mutated form of the TDP-43 gene. According to the grant announcement, SAM001 had improved the function of these animals’ muscles and nerves, “reduced a marker of nerve damage in the blood,” and increased survival without manifesting significant saf … d,” and increased survival without manifesting significant safety concerns. The grant announcement also said that SAM001 had normalized the dysfunctional autophagy, reduced TDP-43 mislocalization, and ameliorated dysfunction in motor neurons from human ALS patients who carry a mutation in C9orf72, which is the most common genetic form of ALS. Under the grant, Samsara will test SAM001 in transgenic ALS-model mice that carry C9orf72 mutations. Other Candidates According to Sams
%PDF-1.4 %���� 1201 0 obj > endobj xref 1201 64 0000000016 00000 n 0000002957 00000 n 0000003135 00000 n 0000003172 00000 n 0000007747 00000 n 0000008165 00000 n 0000008204 00000 n 0000008395 00000 n 0000008573 00000 n 0000008756 00000 n 0000008935 00000 n 0000009050 00000 n 0000009163 00000 n 0000009637 00000 n 0000010084 00000 n 0000012427 00000 n 0000014926 00000 n 0000017263 00000 n 0000017425 00000 n 0000017616 00000 n 0000017876 00000 n 0000017975 00000 n 0000018124 00000 n 0000020607 00000 n 0000023221 00000 n 0000025980 00000 n 0000028628 00000 n 0000030710 00000 n 0000030830 00000 n 0 … �q��x�"������R�'��HŊ: ����h > endobj 1238 0 obj > endobj 1239 0 obj >stream application/pdf MacroGenics_Logo (R) (Large) Adobe Illustrator 24.3 (Windows) 2021-08-24T15:39:14-04:00 2021-08-24T15:39:15-04:00 2021-08-24T15:39:15-04:00 xmp.did:67168291-8a2a-cb4f-9fa6-914577b15419 uuid:2a4ef27b-1393-4a95-8afc-ab489b6ee8f6 uuid:FF79E0A40F2CDE11A40CE833EF0558FA proof:pdf uuid:e3344dbb-bc7f-4721-99e5-627986752052 xmp.did:28DE5C28A5E1E311A4E1AECE6DCE677E uuid:FF79E0A40F2CDE11A40CE … �uܩ����Q�?�3�:���8čT�äH���W�$�5�qZ6�(pYi������[���v���K];�P[��M *J��Da���rFp A��F��j\�� 4��Z��m}��m���*�Y~��(��k�O���� �cCo���G|� �YS?p���|�O��ؗ�x��I!Vj���-Dǧ�MF���=\!��{Ś:h%���� �(�?Y�?��|�▖ �I_�Q��P�}Ȝ�J���fc���3����;���c�����5�s�r߹"�LW�� K�l^����0���ʭ�9�`��2�l�4�b��[:��ʴN� Rb 8���$�Y>�6pmix2��N��'���x+���h�p�����-]g駠2F��c , ڞ�u� ��kc�p�����ڤ�D8��/I�WQ9�F}5f�2pw��ђ#��i7}��q��{4�H�(��#*M�z}{�tuq�J�у�Q�c �sK���h��>���9d�E��;��5ߥFsr]v �� … -8aa2a1c8e915 xmp.did:018011740720681183D1A97B183AFA24 proof:pdf converted from application/x-indesign to application/pdf Adobe InDesign CS6 (Macintosh) / 2018-04-11T09:57:27-04:00 saved xmp.iid:F77F11740720681183D1CABB78ACEF2D 2018-04-17T12:01:20-04:00 Adobe Illustrator CS6 (Macintosh) / saved xmp.iid:861a491c-e1d7-4b7e-beb4-c562e2560ffe 2023-10-17T15:14:15-04:00 Adobe Illustrator 27.9 (Macintosh) / application/pdf Our Living Values Updated 2023 Adobe PDF library 17.00 False … �U��I�$�w ˎa� ��`GAB`fxO��8^���������K� endstream endobj 111 0 obj >stream application/pdf Highlights from Employee Survey 2024-01-11T16:03:39-05:00 2024-01-11T16:03:39-05:00 2024-01-11T16:03:39-04:00 Adobe Illustrator 28.1 (Windows) uuid:2bd96cfc-c8f4-4db0-8a63-e6bc9c54436f xmp.did:3df8ba2c-59bc-4490-aa63-5636f5114e3d uuid:5D20892493BFDB119
2021 Conference | CHDI Foundation Menu CHDI Accelerating Therapeutic Development for Huntington's Disease Search for: Preclinical research Scientific Publications Community Resources Materials Research tools & reagents Mouse Models Clinical biorepository Data sharing & infomatics Preclinical informatics: HDinHD Funding & partnerships Academic Proposals External Partnership Proposals HD expertise & guidance Independent Statistical Standing Committee Clinical outcomes: Rating scales Field guide to HD mouse models News & Video News HD Therapeutics Conference 2026 Presenta … e brains. This work, will develop potent siRNA for targeting MSH3. We will then apply our labs di-valent architecture and show that in the Q111 mouse model, we have 90% silencing of the Msh3 protein. We will also show how this silencing results in complete blockage of somatic expansion. Our work will highlight silencing of MSH3, with clinical grade siRNA, could be another paradigm for treating HD. Top Development of TTX-3360 to treat/prevent HD and other repeat expansion diso … the Huntington's disease research community. × Terms of Use These Terms of Use apply to your use of CHDI Foundation.org, all its sub-domains and all associated services including, but not limited to, e-mail received from CHDIFoundation.org, any of our computer systems, databases or networks connected to CHDIFoundation.org and all its sub-domains (collectively, the "Website"). The Website is being made available for your use by CHDI Foundation, Inc. If you browse or otherwise … t provided or posted on the Website. Links to Other Websites These Terms of Use apply only to the Website. We provide links to other websites, but we do not control the content on those websites or their practices. We are not responsible for other websites' content, information collection practices or use of any information they collect. Links to other websites do not constitute an endorsement by us of those websites or their content, owners or posters. Your Use of Content Co … research activities. Except where otherwise expressly noted or contemplated, we grant you a license to use any content we have provided or posted on the Website under a Creative Commons Attribution 3.0 License. Certain content we have provided or posted on the Website may also be subject to you agreeing to further terms of use specifically coveri
Peter Hamley, PhD | Parkinson's Disease JavaScript is currently disabled. Please enable JavaScript for an optimal experience. Skip to main content Animations Search Email Sign Up Log In Donate Now Home Page Are you looking for: ${result.term} Donate Now Menu Close Clear My Profile My Parkinson’s Library Log In Main navigation Why We Exist Why We Exist Our Mission Our Promise Our Impact Our Agenda Michael's Story Current Partnerships Parkinson's Research The State of the Field Our Research Strategy Key Research Initiatives Parkinson’s Biomarkers Prizes Understanding Parkinson's Understandi … on's Library Educational Guides For Researchers For Researchers Funding What We Fund Funding Opportunities Funded Studies Open Science & Research Integrity Resources Research Tools Data Resources Biospecimens Patient Engagement Research News Podcasts MJFF Scientific Publications Collaboration Collaborative Research Opportunities Industry Partners Working with Us Key Initiatives and Findings PPMI Clinical Study ASAP Initiative GP2 Take Action Take Action Donate Donate Now Ways
7 VCs Funding Longevity Startups in 2026 Contact us News & Insights Cure Innovation Index Healthcare News Investment Founder Stories Cure Original Reports Cure Conversations Racing to Cures: The Cure U.S.-China Biotech Competitiveness Scorecard June 22, 2026 What Makes an Institution Innovative? A Cure Original Report April 29, 2026 Apply for Membership Work in NYC Join Now Cure Residents People of Cure Your Home in NYC Members can access hotdesking, private conference rooms, event space, a cafe, and a gym—all within a healthcare focused environment. Learn More Learn More Attend An Event A … n Holding Stage focus : Seed through Series B, plus their BOLD Longevity Growth Fund Check size range : $1M–$10M; BOLD makes larger growth checks Healthcare focus : Cellular reprogramming, AI in healthcare, regenerative medicine, preventive diagnostics, and organ regeneration Geographic focus : Global, with a presence across the US, Europe, and Asia Assets under management : Over $2 billion Currently deploying : Yes Notable healthcare portfolio companies : Insilico Medicine - … echnology, preventative medicine, and AI in healthcare. The company's BOLD fund, founded with Peter Diamandis in 2023, focuses on growth-stage startups. Longevity Vision Holding was also an investor in unicorn, Freenome. 4. LongeVC Stage focus : Pre-seed through seed Check size range : $500K–$5M Healthcare focus : longevity biotechnology, aging biomarkers, AI-driven drug discovery, regenerative and preventative medicine, and platform technologies that support longevity t … C manages a portfolio of more than 25 companies, and is deploying $120 million (Fund II) . 5. age1 Stage focus : Pre-Seed, Seed, and early Series A Check size range : $500K–$4M Healthcare focus : Age-related disease therapeutics, senolytics, longevity biomarkers, and healthspan biology Geographic focus : U.S. first, with selective Europe presence Assets under management : $35 million Currently deploying : Yes Notable healthcare portfolio companies : Loyal - canine longevity d … , Germany; invests across Europe and the U.S. Assets under management : Current fund size is €300M Currently deploying : Yes Notable healthcare portfolio companies : Reservoir Neuroscience - vascular aging therapy Elevian - regenerative longevity medicine Cellvie - mitochondrial therapy Established in 2000 and based in Karlsruhe, Germany, Kizoo T
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Samsara Therapeutics Jobs + Careers | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies Samsara Therapeutics Teams Samsara Therapeutics Save Saved Oxford 21 Total Employees Year Founded: 2018 View Website Overview Jobs Offices Is This Your Company? Claim Profile Jobs at Samsara Therapeutics Let Your Resume Do The Work Upload your resume to be matched with jobs you're a great fit for. Upload Resume Success! We'll use this to further personalize your experience. No jobs to discover at this time. back to over
FreightWaves - Samsara announced Thursday it has surpassed... Facebook Log In FreightWaves's Post FreightWaves Verified account February 11, 2021 · Shared with Public Samsara announced Thursday it has surpassed more than $300 million in run-rate subscription revenue for the fiscal fourth quarter ended Jan. 30. freightwaves.com Samsara hits milestone with $300M run rate - FreightWaves All reactions: 12 13 comments 1 share Like Comment Most relevant Bojan Seat Of course they made money... eld is not for "saftey" or other crap it's for someone to make money 5y 2 View all 11 re
New avenues for rare disease treatment | Article | Drug Target Review Your browser is not supported Sorry but it looks as if your browser is out of date. To get the best experience using our site we recommend that you upgrade or switch browsers. Find a solution Skip to main content Skip to navigation Site name Site name Mast navigation Become a member Sign In Search our site Search our site Search Menu Close menu Home News Oncology AI Topics Back to parent navigation item Topics Technology Resources Diseases Drugs and therapies Research and development Tools and techniques Business Webinars Wh … ess has risen almost exponentially since Yoshinori Ohsumi was awarded the Nobel Prize in 2016 for his research into its underlying mechanisms. There is a growing body of evidence that any dysfunction or disruption in autophagy is associated with a wide range of disorders including cancer, cardiovascular disease, type 2 diabetes and neurodegenerative diseases. The evidence that autophagy ‘gone wrong’ is a key driver of Alzheimer’s, Parkinson’s, and other neurodegenerative dise
💊 Investing in Therapeutic ventures - baby vc baby vc Subscribe Sign in 💊 Investing in Therapeutic ventures baby vc - Healthcare & Life Sciences Masterclass Series - Key takeaways from Session on 13.06.24 - (Estimated read time: 10 min) Sep 15, 2024 10 Share Written by Loubaba El Ayoubi , Edited by Dr. Anela Vukoja , Annika Bautista and Sarah Luna Mongin 🖤. Last week, we explored what it means to invest in Digital Health ventures , diving into the key investment drivers, business models, and current trends. We also examined the regulatory impact associated with PPP (Public-Private Partn … ent and startup leaders in the field. In particular, we will cover: Speaker and Fund Presentation Defining Drug Modalities Key Investment Criteria in Therapeutics Drug Development Process and Regulatory Bodies VC Strategic Entries, Equity Stories, and Exits : An Apollo Health Case Study IP and Patent Strategy Key Takeaways 1. Speaker and Fund Presentation For this session, we were honored to welcome Dr. Anela Vukoja who brings her wealth of experience. Dr. Vukoja is currently … olecule to market is vastly different from that of a cell therapy. Sometimes, a fund's investment thesis can focus on the technology itself, where innovation comes from the modality which can be seen as a novel tool that can be applied to many diseases. Of course, a use case must be selected to demonstrate its effectiveness. On the other hand, investments can be centered around a specific disease, such as stroke, where the company has identified a particular target for that i … to test the molecule (e.g., small molecule vs. cell therapy). A seed round may fund the company through nomination of a "Development Candidate," which is the molecule or technology selected for safety and toxicology studies in animals. At this point, the chosen candidate cannot be changed, as it is the one intended for human trials. Ticket sizes for this stage typically range from $1 to $5 million, though rounds can reach $10 to $20 million. Once a development cand … ent candidate is secured, companies typically raise a Series A round, which can fund them through safety and toxicology assessment or all the way through clinical Proof of Concept. Individual investor ticket sizes here usually range from $5 to $10 million. After clinical Proof of Concept , several paths are possible: the company could go public,
The South African Medical Association Facebook Group | 👉🏽 Partnerships that strengthen healthcare conversations matter, and we’re proud to have Discovery as a Silver Sponsor of the SAMA Health Summ...
Samsara Therapeutics leadership team Skip to content Leadership Contact Leadership Meet the team Timothy Piser, PhD President and Head of R&D Dr. Timothy Piser is a neuropharmacologist with more than 25 years of experience leading neuroscience drug discovery and development in large public pharmaceutical companies and private VC-funded start-up biotech. During his early career at AstraZeneca, he led drug discovery programs in psychiatry and neurology through IND enabling studies and a global drug development program in Treatment Resistant Depression through Phase 2 clinical trials. More re … since been helping shape R&D strategy and clinical development plans in the fund’s venture creations. She takes an active role and supports companies both as an advisor and operator as needed. She currently serves on the board of directors of several companies including Samsara Therapeutics, Booster Therapeutics and Refoxy Pharmaceuticals. In addition, Anela helps evaluate new investment opportunities and initiates company creation projects, especially in the area of neur … t the Apollo portfolio. Nils and the founding team have successfully raised two fund generations, hired the senior team, and led investments as well as follow-on investments in Apollo’s portfolio companies. Nils studied business in Hamburg and at UC Santa Barbara (UCSB) in California, and he completed the EO Entrepreneurial Masters Program at MIT Science Oxford Centre Quarry Road, Headington Oxford, OX3 8SB UK 50 Milk Street Boston MA 02108 USA Contact Send Privacy
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Treating Neurodegeneration by Improving Autophagy. Skip to content Leadership Contact Treating Neurodegenerative Disease by Restoring Autophagy Samsara Therapeutics Our Mission Samsara Therapeutics: Treating Neurodegeneration by Improving Autophagy At Samsara Therapeutics, we’re on a mission to unlock the full potential of autophagy activation in combating age-related neurodegenerative diseases. Our innovative approach aims to delay the progression of several debilitating conditions, offering new possibilities for patients and their families. get in touch Our Foundation Founded in 2019 a
Apollo Health Ventures: Investoren starten neuen Biotech-Fonds Menü Menü Startseite Unternehmen Mittelstand Familienunternehmer Apollo Health Ventures: Investoren fördern Biotech-Start-Ups wie Samsara Therapeutics Apollo Health Ventures : Millionen für längeres Leben: Investoren starten neuen Biotech-Fonds Der Markt rund um das ewige Leben boomt. Zwei Firmenbauer setzen zusammen mit Wissenschaftlern zur Seriengründung deutscher Biotech-Unternehmen an. Larissa Holzki , Jürgen Klöckner , Maike Telgheder 26.08.2020 - 18:00 Uhr Apollo Health Ventures: Kapital für ein längeres Leben. Foto: dpa Düss … t Media Group GmbH & Co. KG Please enable JavaScript to continue using this application.